Imagine checking important health metrics from blood sugar to hormones with the same ease as checking your steps on a smartwatch. That’s the promise behind Inito, a healthtech startup that’s just raised $29 million in a fresh funding round to scale its at-home diagnostics platform.

Founded with the vision of bringing clinical-grade testing out of labs and into people’s hands, Inito has developed smart diagnostic devices that pair with a smartphone app. Users can test for a range of biomarkers including glucose levels for diabetes tracking, hormone panels for fertility insights, liver function indicators, and more all with rapid results and personalised interpretation.

This funding will accelerate Inito’s expansion across markets in Asia, Europe and the U.S., while powering further product development and navigation of regulatory clearances. The company is betting big on the global shift toward preventive and personalised healthcare where early detection and continual monitoring help people manage conditions proactively rather than reactively.

What makes Inito’s approach stand out is its focus on clinical fidelity, user experience, and data-driven insights that integrate with everyday life. By enabling users to gather real-time health data at home, the platform hopes to reduce unnecessary clinic visits, lower healthcare costs, and empower individuals to understand their bodies better.

And investors are clearly confident. The $29 million raise reflects growing enthusiasm for tools that decentralise diagnostics, harness data intelligently, and support health beyond hospital walls.

As at-home care gains momentum  partly accelerated by pandemic-era shifts Inito’s platform may soon become a regular part of how people manage their health journeys: quick tests in bedrooms and kitchens, actionable insights on their phones, and clinicians equipped with richer longitudinal data to personalise care plans.